Protein tyrosine phosphorylation in smooth muscle: A potential coupling mechanism between receptor activation and intracellular calcium

Proceedings of the Society for Experimental Biology and Medicine

Volumn 214, Issue 4, 1997, Pages 285-301

  Di Salvo, Joseph ^a   Nelson, Stephanie Raatz ^a   Kaplan, Nihal ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ARGIPRESSIN; CALCIUM; CARBACHOL; CELL RECEPTOR; EGTAZIC ACID; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; LANTHANUM CHLORIDE; PHENYLEPHRINE; PHOSPHOLIPASE C; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEROTONIN RECEPTOR; TYROSINE; VANADIC ACID;

CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER;

ANIMALS; CALCIUM; MUSCLE, SMOOTH, VASCULAR; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 0030919582     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Tsein RW, Tsein RY. Calcium channels, stores, and oscillations. Annu Rev Cell Biol 6:715-760, 1990.
2. Pozzan T, Rizzuto R, Volpe P, Meldolesi J. Molecular and cellular physiology of intracellular calcium stores. Physiol Rev 74:595-636, 1994.
3. McDonald TF, Pelzer S, Trautwein W, Pelzer DJ. Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol Rev 74:365-507, 1994.
4. Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature 372:231-236, 1994.
5. 2+ in smooth muscle. Annu Rev Physiol 51:129-145, 1989.
6. 2+ homeostasis in vascular smooth muscle. J Vasc Res 32:207-219, 1995.
7. O'Donnell ME, Owen NE. Regulation of ion pumps and carriers in vascular smooth muscle. Physiol Rev 74:683-721, 1994.
8. Wickman K, Clapham DE. Ion channel regulation by G proteins. Physiol Rev 756:865-885, 1995.
9. Parsons JT, Weber MJ. Genetics of src: Structure and functional organization of a protein tyrosine kinase. Curr Top Microbiol Virol 147:80-127, 1990.
10. Cantley LG, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soitaff S. Oncogenes and signal transduction. Cell 64:281-302, 1991.
11. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem 62:453-481, 1993.
12. Williams LT. Signal transduction by the platelet-derived growth receptor. Science 243:1564-1570, 1989.
13. Hartshorne DJ, Matsushima S, Ito M, Guerriero V, Kawamura T Jr. Myosin light chain kinase: Structure-function relationships. Jpn J Pharmacol 58:17P-22P, 1992.
14. Barron JT, Barany M, Barany K, Storti RV. Reversible phosphorylation and dephosphorylation of the 20,000-dalton light chain of myosin during the contraction cycle of arterial smooth muscle. J Biol Chem 255:6238-6244, 1980.
15. Walker JS, Wingard CJ, Murphy RA. Energetics of crossbridge phosphorylation and contraction in vascular smooth muscle. Hypertension 23:1106-1112, 1994.
16. Kamm KE, Stull JT. Regulation of smooth muscle contractile elements by second messengers. Annu Rev Physiol 51:299-314, 1989.
17. 2++ sensitive bovine aortic actomyosin. Proc Soc Exp Biol Med 158:410-414, 1978.
18. O'Dell TJ, Kandel ER, Grant GN. Long term potentiation hippocampus is blocked by tyrosine kinase inhibitors. Nature 353:558-560, 1991.
19. Zenner G, Dirk zur Hausen J, Burn P, Mustelin T. Towards unraveling the complexity of T-cell signal transduction. Bioessays 17:967-975, 1995.
20. Vostal JG, Jackson WL, Shulman NR. Cytosolic and stored calcium antagonistically control tyrosine phosphorylation of specific platelet proteins. J Biol Chem 266:16911-16916, 1991.
21. 2+ entry and protein-tyrosine phosphorylation are inhibited by the tyrosine kinase inhibitors genistein and methyl-2,5-dihydroxycinnamate in fura-2-loaded human platelets. J Biol Chem 268:18151-18156, 1993.
22. Hunter T. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signalling. Cell 80:225-236, 1995.
23. Ely CM, Oddie K, Litz JS, Rossomando AJ, Kanner SB, Sturgill TW, Parsons SJ. A 42-kD tyrosine kinase substrate linked to chromaffin cell secretion exhibits an associated MAP kinase activity and is highly related to a 42-kD mitogen-stimulated protein in fibroblasts. J Cell Biol 110:731-742, 1990.
24. c-src tyrosine kinase, myristylation, and modulatory domains are required for enhanced mitogenic responsiveness to epidermal growth factor seen in cells overexpressing c-src. Mol Cell Biol 9:1536-1544, 1989.
25. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212, 1990.
26. Margolis B, Bellot F, Honegger AM, Ullrich A, Schlessinger J, Zilberstein A. Tyrosine kinase activity is essential for the association of phospholipase C-γ with the epidermal growth factor receptor. Mol Cell Biol 10:435-441, 1990.
27. Bilder GE, Krawiec JA, McVety K, Gazit A, Gilon C, Lyall R, Zilberstein A, Levitzki A, Perrone MH, Schreiber AB. Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am J Physiol 260:C721-C730, 1991.
28. Koch CA, Anderson D, Moran MF, Ellis C, Pawson T. SH2 and SH3 domains: Elements that control interactions of cytoplasmic signalling proteins. Science 252:668-674, 1991.
29. Heldin CH. SH2 domains: Elements that control protein interactions during signal transduction. TIBS 16:450-452, 1991.
30. Morgan KG, DeFeo TT, Wenc K, Weinstein R. Alterations of excitation contraction coupling by platelet-derived growth factor in enzymatically isolated and cultured vascular smooth muscle cells. Pflugers Arch 405:77-79, 1985.
31. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 57:443-478, 1988.
32. Ozaki Y, Yatomi Y, Jinnai Y, Kume S. Effects of genistein, a tyrosine kinase inhibitor, on platelet functions. Biochem Pharmacol 46:395-403, 1993.
33. Thyberg J, Hedin U, Sjolund M, Palmberg L, Bottger BA. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis 10:966-990, 1990.
34. Schwartz SM, Heimark RL, Majesky MW. Developmental mechanisms underlying pathology of arteries. Physiol Rev 70:1177-1209, 1990.
35. Ross R. Growth, regulatory mechanisms, and formation of the lesions of atherosclerosis. Ann NY Acad Sci 748:1-6, 1995.
36. Berk BC, Brock TA, Webb RC, Taubman MB, Atkinson WJ, Gimbrone MA, Alexander RW. Epidermal growth factor, a vascular smooth muscle mitogen, induces rat aortic contraction. J Clin Invest 75:1083-1086, 1985.
37. Berk BC, Alexander RW, Brock TA, Gimbrone MA, Webb RC. Vasoconstriction: A new activity for platelet-derived growth factor. Science 232:87-90, 1986.
38. Berk BC, Alexander RW. Vasoactive effects of growth factors. Biochem Pharmacol 38:219-225, 1989.
39. Gan BS, MacCannell KL, Hollenberg MD. Epidermal growth factor urogastrone causes vasodilatation in the anesthetized dog. J Clin Invest 80:199-206, 1987.
40. Bassett JE, Bowen-Pope DF, Takayusi M, Dacey RG. Platelet-derived growth factor does not constrict rat intracerebral arterioles in vitro. Microvasc Res 35:368-373, 1988.
41. June CH, Fletcher MC, Ledbetter JA, Schieven GL, Siegel JN, Phillips AF, Samelson LE. Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction. Proc Natl Acad Sci 97:7722-7726, 1990.
42. 2+ elevation and mobilization in T cells. J Biol Chem 267:7154-7159, 1992.
43. Lane PJL, Ledbetter JA, McConnell FM, Draves K, Deans J, Schievers GL, Clark A. The role of tyrosine phosphorylation in signal transduction through surface Ig in human B cells. Inhibition of tyrosine phosphorylation prevents intracellular calcium release. J Immunol 146:715-722, 1991.
44. lck by the CD45 phosphotyrosine phosphatase. Proc Natl Acad Sci U S A 86:6302-6306, 1989.
45. Mustelin T, Coggeshall KM, Isakov N, Altman A. T-cell antigen receptor-mediated activation of phospholipase C requires tyrosine phosphorylation. Science 274:1584-1587, 1990.
46. c-src kinase activity in bovine conary extracts is stimulated by ATP. Biochem Biophys Res Commun 153:388-394, 1988.
47. c-src kinase activity in extracts from vascular smooth muscle. J Biol Chem 264:10773-10778, 1989.
48. c-src kinase. Adv Prot Phosphatases 5:93-104, 1989.
49. Simon M, Dress B, Kornberg T, Bishop JM. The nucleotide sequence and the tissue-specific expression of drosophila c-src. Cell 42:831-840, 1985.
50. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262:5592-5595, 1987.
51. Onoda T, Iinuma H, Sasaki Y, Hamada M, Issiki K, Naganawa H, Takeuchi T. Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus. J Natl Prod 52:1252-1257, 1989.
52. Gazit AP, Yaish C, Gilon C, Levitzki A. Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem 32:2344-2352, 1989.
53. Yamaki H, Iguchi-Ariga SM, Ariga H. Inhibition of c-myc gene expression in murine lymphoblastoma cells by geldandmycin and herbimycin, antibiotics of benzoquinoid ansamycin group. J Antibiot 42:604-610, 1989.
54. Di Salvo J, Steusloff A, Semenchuk LA, Satoh S, Kolquist K, Pfitzer G. Tyrosine kinase (TK) inhibitors suppress agonist-induced contraction in smooth muscle. FASEB J 6:A26, 1992.
55. 2+ sensitivity for contraction of smooth muscle. Can J Physiol Pharmacol 72:1434-1439, 1994.
56. Di Salvo J, Semenchuk LA, Lauer J. Vanadate-induced contraction of smooth muscle and enhanced protein tyrosine phosphorylation. Arch Biochem Biophys 304:386-391, 1993.
57. 2+ sensitivity in smooth muscle by genistein and protein tyrosine phosphorylation. Arch Biochem Biophys 320:236-242, 1995.
58. Yang S-G, Saifeddine M, Hollenberg MD. Tyrosine kinase inhibitors and the contractile action of epidermal growth factor, urogastrone and other agonists in gastric smooth muscle. Can J Physiol Pharmacol 70:85-93, 1992.
59. Hollenberg MD. Tyrosine kinase pathways and the regulation of smooth muscle contractility. TIPS 15:108-114, 1994.
60. 2+ mobilization in swine carotid artery. Am J Physiol 268:1425-1429, 1995.
61. Gressesr MJ, Tracey AS, Stankiewicz PJ. The interaction of vanadate with tyrosine kinases and phosphatases. Adv Prot Phosphatases 4:35-57, 1987.
62. Tonks NK, Charbonneau H. Protein tyrosine dephosphorylation and signal transduction. TIBS 14:497-500, 1990.
63. Hamaguchi M, Grandori C, Hanafusa H. Phosphorylation of cellular proteins in Rous Sarcoma virus-infected cells: Analysis use of anti-phosphotyrosine antibodies. Mol Cell Biol 8:3035-3042, 1988.
64. Shimada T, Shimamura K, Sunano S. Effects of sodium vanadate on various types of vascular smooth muscles. Blood Vessels 23:113-124, 1986.
65. Sanchez-Ferrer CF, Marin J, Lluch M, Valverde A, Salaices M. Actions of vanadate on vascular tension and sodium pump activity in cat isolated cerebral and femoral arteries. Br J Pharmacol 93:53-60, 1988.
66. Di Salvo J, Kolquist K, Lauer J, Semenchuk LA. Vanadate-induced contraction of smooth muscle is associated with protein-tyr phosphorylation. FASEB 6:A1545, 1992.
67. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440-3450, 1985.
68. Williams DA, Becker PL, Fay FS. Regional changes in calcium underlying contraction of single smooth muscle cells. Science 235:1644-1648, 1987.
69. 2+ buffering and coupling to AVP-evoked inositol phosphate synthesis. Am J Physiol 266(Cell Physiol 35):C276-C283, 1994.
70. 2+ in cultured arterial smooth muscle cells using Fura-2 and digital imaging microscopy. Cell Calcium 11:221-231, 1991.
71. Hughes AD, Schacter M. Multiple pathways for entry of calcium and other divalent cations in a vascular smooth muscle cell line (A7r5). Cell Calcium 15:317-330, 1994.
72. 8]-vasopressin-activated increases in protein tyrosine phosphorylation and cellular calcium in A7r5 aortic smooth muscle cells. Arch Biochem Biophys 326:271-280, 1996.
73. Di Salvo J, Kaplan N, Semenchuk LA. Protein tyrosine phosphorylation and regulation of intracellular calcium in smooth muscle. In: Barany M, Ed. Biochemistry of Smooth Muscle Contraction. New York: Academic Press, pp 283-293, 1996.
74. 2+ spiking in single smooth muscle cells. EMBO J 12:5287-5291, 1993.
75. Ohta T, Ito S, Nakazato Y. All-or-nothing responses to carbachol in single intestinal smooth muscle cells of rat. Br J Pharmacol 112:972-976, 1994.
76. Semenchuk LA, Di Salvo J. Receptor-activated increases in intracellular calcium and protein tyrosine phosphorylation in vascular smooth muscle cells. FEBS Lett 370:127-130, 1995.
77. Liu Y, Sturek M. Cellular mechanisms for tyrosine kinase inhibitor-induced attenuation of myoplasmic calcium response to endothelin. Biophys J 70:A21, 1996.
78. Toma C, Jensen PE, Prieto D, Hughes A, Mulvany MJ, Aalkjaer C. Effects of tyrosine kinase inhibitors on the contractility of rat mesenteric arteries. Br J Pharmacol 114:1266-1272, 1995.
79. + currents by tyrosine kinase inhibitors genistein and ST 638. Circ Res 76:310-316, 1995.
80. Tsuda T, Kawahara Y, Shii K, Koide M, Ishida Y, Yokoyama M. Vasoconstrictor-induced protein-tyrosine phosphorylation in cultured vascular smooth muscle cells. FEBS Lett 285:44-48, 1991.
81. Molloy CJ, Taylor DS, Weber H. Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aortic smooth muscle cells. J Biol Chem 268:7338-7345, 1993.
82. Vogel W, Lammers R, Huang J, Ullrich A. Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science 259:1611-1614, 1993.
83. Feng G-S, Hui C-C, Pawson T. SH2-containing phosphotyrosine phosphatase as a target of protein tyrosine kinases. Science 259:1607-1611, 1993.
84. Moran MF, Polakis P, McCormick F, Pawson T, Ellis C. Protein-tyrosine kinases regulate the phosphorylation, protein interactions, subcellular distribution, and activity of p21ras GTPase-activating protein. Mol Cell Biol 11:1804-1812, 1991.
85. Ellis C, Moran M, McCormick F, Pawson T. Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases. Nature 343:377-381, 1990.
86. Hescheler J, Klinz F-J, Schultz G, Wittinghofer A. Ras proteins activate calcium channels in neuronal cells. Cell Signal 3:127-133, 1991.
87. Moran MF, Koch CA, Anderson D, Ellis C, England L, Martin GS, Pawson, T. Src homology region 2 domains direct protein-protein interactions in signal transduction. Proc Natl Acad Sci U S A 87:8622-8626, 1990.
88. Adam LP, Hathaway DR. Identification of mitogen-activated protein kinase phosphorylation sequences in mammalian h-caldesmon. FEBS Lett 32:56-60, 1993.
89. Wijetunge S, Aalkjaer C, Schacter M, Hughes AD. Tyrosine kinase inhibitors block calcium channel currents in vascular smooth muscle cells. Biochem Biophys Res Commun 189:1620-1623, 1992.
90. c-src increases voltage-operated calcium channel currents in vascular smooth muscle cells. Biochem Biophys Res Commun 217:1039-1044, 1995.
91. 2+ channel antagonist inhibit Ba1 entry in A10 vascular smooth muscle cells (VSMC). Biophys J 70:A286, 1996.
92. Harnick DJ, Jayaraman T, Ma Y, Mulieri P, Go LO, Marks AR. The human type 1 inositol 1,4,5-trisphosphate receptor from T lymphocytes. J Biol Chem 270:2833-2840, 1995.
93. Ondrias K, Jayaraman T, Marks AR. Functional association between Fyn kinase and the inositol 1,4,5-triphosphate receptor. Biophys J 70:A20, 1996.
94. Chalovich JM, Greene LE, Eisenberg E. Crosslinked myosin subfragment-1: A stable analogue of the subfragment-1.ATP complex. Proc Natl Acad Sci U S A 80:4909-4913, 1983.
95. Marrero MB, Paxton WG, Duff JL, Berk BC, Bernstein KE. Angiotensin II stimulates tyrosine phosphorylation of phospholipase C-γ1 in vascular smooth muscle cells. J Biol Chem 269:10935-10939, 1994.
96. Nakanishi O, Shibasaki F, Hidaka M, Homma Y, Takenawa T. Phospholipase C-γ1 associates with viral and cellular src kinases. J Biol Chem 268:10754-10759, 1993.
97. c-src antibodies inhibits the angiotensin II activation of phospholipase C-γ1 in rat aortic smooth muscle cells. J Biol Chem 270:15734-15738, 1995.